A Study of Oral MBQ-167 in Participants With Advanced Breast Cancer

A Phase 1, open-label, dose-escalation clinical trial of MBQ-167 in participants with advanced Breast Cancer for whom Standard of Care (SOC) has failed or has proven intolerable.

Trial Details

NCT ID
NCT06075810
Phase
PHASE1
Sponsor
MBQ Pharma
Status
RECRUITING
Cancer Type
Breast Cancer
Interventions
  • MBQ-167
Locations (sample)
  • Beverly Hills, California, United States|34.07362,-118.40036
  • Sarasota, Florida, United States|27.33643,-82.53065
  • Nashville, Tennessee, United States|36.16589,-86.78444
  • San Juan, Puerto Rico|18.46633,-66.10572

Key Eligibility Criteria

  • The investigator will evaluate these and other criteria to determine whether a participant can be included in this study.
  • Histologically and/or cytologically confirmed advanced breast cancer which has progressed after treatment with approved therapies or for which ther…
  • Participants with known brain metastases may be eligible if specific conditions are met.
  • Life expectancy ≥6 months, in the opinion of the investigator, after starting MBQ-167.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Breast Cancer Trials on Trialify →